randomized controlled trial

HIV/AIDS

Unfavourable laws, stigma, violence, and discrimination cause sex workers’ vulnerability to ill health, social exclusion and human rights violations. Sex workers face these to varying degrees in all cultures from Switzerland to Swaziland, Canada to Cambodia. This guide, published by the International Network of Sex Work Projects, outlines their understanding of HIV and sex work and sets out their global agenda for change. This news interview features members of the Network of Sex Work Projects. They describe the challenges that they face in Uganda and the way that they are subject to stigma and discrimination and excluded from development policy

Tenofovir

The CAPRISA 004 trial assessed effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel with placebo gel in sexually active, HIVuninfected18 to 40 year-old women in urban and rural KwaZulu-Natal, South Africa HIV serostatus, safety,sexual behavior and gel and condom use were assessed at monthly follow-up visits for 30 months.

microbicide

prevention

The expansion of access to antiretroviral therapy for millions of persons living with HIV in low-income countries has been lauded by many. However, the investment in such programs has at the same time been criticized by others, who claim diversion of resources from HIV prevention efforts and from other important health threats in these same countries. Yet, the time is right to recommit to the goal Article in the Lancet, Early Online Publication, 11 October 2011. Background The aim of Avahan, the India AIDS Initiative, was to reduce HIV transmission in the general population through large-scale prevention interventions focused on high-risk

Contraceptive Used in Africa May Double Risk of HIV

By Pam Belluck for the New York Times, 3 October 2011. The most popular contraceptive for women in eastern and southern Africa, a hormone shot given every three months, appears to double the risk the women will become infected with H.I.V., according to a large study published Monday. And when it is used by H.I.V.-positive women, their male partners are twice as likely to become infected than if the women had used no contraception. The findings potentially present an alarming quandary for women in Africa. Hundreds of thousands of them suffer injuries, bleeding, infections and even death in childbirth from

HIV/AIDS

Tenofovir

microbicide

prevention

Contraceptive Used in Africa May Double Risk of HIV

Keyword search